Integrated Professional (IP) Law Leaders’ Post

Unveiling the Future: 60 Breakthrough Insights into the Revolutionary World of Cancer Research provides an in-depth look into the latest advancements in cancer research. The article covers the rise of immunotherapy, the precision of targeted therapies, the significance of the tumor microenvironment, the potential of liquid biopsies, the power of DNA sequencing, and the transformative capabilities of Artificial Intelligence in oncology. This exploration into the revolutionary world of cancer research offers hope for a future where cancer can be conquered.

Unveiling the Future: 60 Breakthrough Insights into the Revolutionary World of Cancer Research provides an in-depth look into the latest advancements in cancer research. The article covers the rise of immunotherapy, the precision of targeted therapies, the significance of the tumor microenvironment, the potential of liquid biopsies, the power of DNA sequencing, and the transformative capabilities of Artificial Intelligence in oncology. This exploration into the revolutionary world of cancer research offers hope for a future where cancer can be conquered.

#liquidbiopsy #pregnancy #maternal #cancer https://lnkd.in/gS9Gxv_Q The ability of prenatal cell-free DNA sequencing to incidentally detect occult maternal malignancies was first documented over a decade ago, yet coordinated follow-up of pregnant people who receive these results is still lacking in many countries. Here we provide a call to action for oncologists to become more involved in diagnosing and managing these cases.

Should MRD negativity be accepted as a surrogate endpoint for clinical trials in myeloma - Ben Derman https://lnkd.in/gaYMuZkh #oncodaily #oncology #cancer #MRD #myeloma #clinicaltrials #FDA #surrogateendpoint #OverallSurvival #PFS #mmsm #mmMRD

Communication with cancer patients, their family and caregivers (GP, nurses, other specialists) is of outmost importance. As oncologist, we can rely on clinical trials (and our personal experience and the one from our peers) to discuss patient's outcome and prognosis (overall survival, progression free survival, incidence and severity of adverse events, response rate of a given treatment). However, each patient is singular and thus prediction is always complicated and a matter of debate. And even if we "know", how to translate the message to the patient and make sure he understood, is an constant challenge. We regularly receive interrogations whether our patients or their family have been informed about the status (curative, not curative) of their disease, or its evolution (terminally ill or not). This American Society of Clinical Oncology (ASCO) Post answers to some of these important questions. https://lnkd.in/e5rpydm2

🔬 Exciting breakthrough in healthcare research! 💡Researchers have identified a shared molecular mechanism found in both cancer and pregnancy, revealing insights into immune system suppression. 👉Read more in the news article: https://bit.ly/4bzN9MM 🔍This discovery could reshape our understanding of disease progression and treatment strategies. 🌟 Dive into the latest findings and implications for clinical practice. Stay ahead with cutting-edge knowledge in oncology and maternal health! Credit: Cell Press #ICB #HealthcareResearch #CancerTreatment #Pregnancy #ImmuneSystem #MedicalBreakthrough #meded #eMednews

In our commentary published today in the #jco #journalofclinicaloncology the American Society of Clinical Oncology (ASCO) official journal, we discusss: The importance of surrogate endpoints like PFS (progression-free survival). Patients with cancer need effective medicines quickly, but waiting for overall survival to read out can increase time to approval and may lead to potential loss of years for thousands. Post-progression survival affects OS hazard ratios, reducing statistical power. Overall, statistically significant PFS gains indicate that therapies probably have real biological effects. #oncology #cancerresearch #healthcare #surrogateendpoints #clinicaltrials #drug #drugdeveloment Grateful to be able to work with colleagues Di Maria Jiang Gerald Batist Geoffrey, Liu David Stewart & Tim Ramsay

Ovarian cancer and #pregnancy: What to know For consultation with Gynaecologic Oncologist, please call at ph +91 9820458696 or visit the website by clicking on the link https://buff.ly/3rXKU51 . . . #ovariancancer #ovariancancersymptoms #cancer #ovariancancerawareness #cancerawareness #cancersurvivor #ovariancancersurvivor #womenshealth #ovariancancerresearch

While the lack of estrogen in Depo (and other forms of progestin-only birth control like O-pill) was hypothesized not to increase breast cancer risk like the pill does, the facts tell a different story. A 2023 study out of Oxford University found that Depo use increased breast cancer risk just as much as the pill, even though it doesn’t contain estrogen [8]. Both combined oral contraceptives and Depo-Provera use increased women’s breast cancer risk by 20-30%. Read the article to learn more and access the studies: https://lnkd.in/gFdcg7S9 #depo #birthcontrolissues #cancerrisk

Evaluating Major Pathologic Response (MPR) and Pathologic Complete Response (pCR) as potential surrogate endpoints for survival in randomized controlled trials (RCTs) is of significant interest in oncology research, particularly in the context of neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC). In clinical trials, MPR is often defined as a specific threshold of tumor regression, such as ≥ 50% reduction in viable tumor cells. Assessing MPR provides insights into the effectiveness of neoadjuvant therapy in inducing tumor regression and potentially improving patient outcomes. On the other hand, achieving pCR signifies the absence of viable tumor cells in the resected specimen post-neoadjuvant treatment, correlating with favorable long-term outcomes, including improved survival rates. The rationale behind using these surrogate endpoints lies in their ability to predict treatment efficacy and patient prognosis in a more timely manner than traditional survival endpoints, facilitating quicker decision-making in clinical practice. Despite their potential utility, challenges such as variability in pathologic assessment criteria and the impact of residual disease post-MPR or pCR on long-term prognosis necessitate careful consideration. Continued research endeavors are crucial to further validate the reliability of these surrogate endpoints and their implications for enhancing patient care and treatment outcomes. Read the full article here: https://lnkd.in/gg_h_aUA #OncologyResearch #ImageAnalysisGroup #NSCLC #NeoadjuvantTherapy #ClinicalTrials #Solidtumors #PatientCare